01The category's loudest conversation
INDEPENDENT PEPTIDE GUIDE
Big promise. Fast change. Clear eyes.
Peplyst follows why peptides attract attention, what human evidence exists, and what FDA actions have—and have not—changed.
Independent by designNo clinicsNo vendorsNo treatment sales
WHAT HAPPENED
Six peptide families received favorable advisory votes
WHAT IT MEANSThey are still not FDA approved, and no final legal change has occurred
WHY PEPLYST EXISTS
The interest is real. The evidence is uneven. The rules are changing.
All three can be true at once. Peplyst takes the field seriously without treating attention as proof.
Independent peptide analysis for a fast-moving field.
01Start with curiosityUnderstand why a compound captured attention.
02Separate promise from proofHuman data never blends into animal or mechanistic evidence.
03Keep the record permanentEvery regulatory step stays visible as the story changes.
THE FIELD, AT A GLANCE
Open the field guide →Why these peptides attract attention.
Browse by common areas of interest. These categories describe the conversation, not proven benefits.
02Mitochondria, aging, and the long game
Metabolic & longevity
03Focus, resilience, and restoration
Brain & sleep
04Visible effects and host-defense biology
Skin, immune & inflammation
FIELD NOTE 001THE NAME DRIVING THE CONVERSATION
BPC-157
Recovery & repair
WHY PEOPLE CARE
BPC-157 has become a shorthand for faster recovery in peptide culture, with conversation spanning tendons, joints, and the gut.
CURRENT ASSESSMENTThe FDA review focused on ulcerative colitis and found limited human clinical evidence plus major product-characterization and safety uncertainty.
Read the full BPC-157 record →POPULAR DOES NOT MEAN PROVEN
Start with the human evidence.
For every peptide, Peplyst keeps human studies separate from animal and laboratory research. That makes it easier to see what is promising, what is uncertain, and what has not been tested in people.
THE STATUS BOARD
Compare side by side →17 compounds. One clean read.
Search, filter, compare, and build a watchlist without digging through agency documents.
BPC-157Ulcerative colitis
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
KPVWound healing and inflammatory conditions
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
TB-500Wound healing
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
MOTS-cObesity and osteoporosis
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
EpitalonInsomnia
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
SemaxCerebral ischemia, migraine, and trigeminal neuralgia
Committee favored
No final legal changeNot FDA approved
FDA actionTiming not announced
Emideltide / DSIPOpioid withdrawal, chronic insomnia, and narcolepsy
Committee did not favor
No final legal changeNot FDA approved
FDA responseTiming not announced
LL-37Uses to be specified in forthcoming meeting materials
Awaiting review
No final legal changeNot FDA approved
FDA advisory meetingBefore the end of Feb 2027
GHK-CuUses to be specified in forthcoming meeting materials
Awaiting review
No final legal changeNot FDA approved
FDA advisory meetingBefore the end of Feb 2027
Dihexa acetateUses to be specified in forthcoming meeting materials
Awaiting review
No final legal changeNot FDA approved
FDA advisory meetingBefore the end of Feb 2027
Melanotan IIUses to be specified in forthcoming meeting materials
Awaiting review
No final legal changeNot FDA approved
FDA advisory meetingBefore the end of Feb 2027
PEG-MGFUses to be specified in forthcoming meeting materials
Awaiting review
No final legal changeNot FDA approved
FDA advisory meetingBefore the end of Feb 2027
AOD-9604Obesity
Committee did not favor
No final legal changeNot FDA approved
FDA responseTiming not announced
CJC-1295Growth hormone deficiency
Committee did not favor
No final legal changeNot FDA approved
FDA responseTiming not announced
Ipamorelin acetatePostoperative gastrointestinal recovery (study context)
FDA safety concern
FDA safety concernNot FDA approved
Further FDA evaluationTiming not announced
Selank acetateGeneralized anxiety disorder and neurasthenia (study context)
FDA safety concern
FDA safety concernNot FDA approved
Further FDA evaluationTiming not announced
Thymosin alpha-1Hepatitis B, hepatitis C, HIV, COVID-19, vaccine response, cancers, sepsis, transplant infections, COPD, and ME/CFS
Committee did not favor
No final legal changeNot FDA approved
FDA responseTiming not announced
HEADLINE DECODER
Translate the claim before you trust it.
Choose the phrase you saw. Peplyst separates the real regulatory signal from the conclusion people often jump to.
✓
Built around FDA terminologyPlain English, with the distinction that matters preserved.
Advisory signalPEPLYST READOUT
What it means
An expert committee sent a non-binding recommendation to FDA.
What it does not mean
It is not FDA approval, final permission to compound, or proof that the peptide works.
→
What to watch next
Watch for an FDA proposal, enforcement policy, or final agency action.
UPCOMING REVIEWS
Five compounds awaiting an FDA advisory meeting.
FDA says the meeting will occur before the end of February 2027. The exact date and full briefing materials are still pending.
01
FDA review announcedLL-37
FDA says the advisory review will happen before the end of February 2027; the exact date is still pending.
NextFDA advisory meeting→
02
FDA review announcedGHK-Cu
FDA says the advisory review will happen before the end of February 2027, including the nominated non-injectable context.
NextFDA advisory meeting→
03
FDA review announcedDihexa acetate
FDA says the advisory review will happen before the end of February 2027. It reports no identified human exposure data.
NextFDA advisory meeting→
04
FDA review announcedMelanotan II
FDA says the advisory review will happen before the end of February 2027 and identifies published serious adverse-event case reports.
NextFDA advisory meeting→
05
FDA review announcedPEG-MGF
FDA says the advisory review will happen before the end of February 2027. It reports no identified human exposure data.
NextFDA advisory meeting→
LATEST CHANGES
What changed. What didn’t.
Every event stays in the record, so the story cannot quietly rewrite itself.
View the permanent timeline01
Schedule update
↗LL-37
LL-37 remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.02
Schedule update
↗GHK-Cu
GHK-Cu remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.03
Schedule update
↗Dihexa acetate
Dihexa acetate remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.YOUR PEPLYST WATCHLIST
Open the status board →Save the compounds you want to revisit.
Your watchlist stays on this device. You can also join the waitlist for a future material-change alert service; email delivery is not active yet.